Skip to main content
Shanghai Bio-heart Biological Technology Co., Ltd. logo

Shanghai Bio-heart Biological Technology Co., Ltd. — Investor Relations & Filings

Ticker · 2185 ISIN · CNE100004JH3 HKEX Manufacturing
Open in API
Filings indexed 220 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2185

About Shanghai Bio-heart Biological Technology Co., Ltd.

http://www.bio-heart.com

Shanghai Bio-heart Biological Technology Co., Ltd. is a leading interventional cardiovascular device company focused on developing advanced therapies to address unmet medical needs, particularly in coronary and peripheral artery diseases and hypertension. The core business centers on the research, development, and manufacturing of innovative medical devices, primarily specializing in Bioresorbable Scaffolds (BRS) and Renal Denervation (RDN) systems. The company maintains a robust quality management system compliant with ISO13485/YY0287 standards, supported by approximately 4000m² of Class 10,000 cleanroom facilities for high-quality device production and testing.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT REGISTRATION OF IBERIS RDN SYSTEM IN VIETNAM
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by Shanghai Bio-heart regarding the registration of a medical device in Vietnam. It is neither a financial report nor an earnings release, nor does it involve board changes, dividends, capital structure, or legal proceedings. It is a corporate disclosure/update not fitting specialized categories and thus falls under the general “Regulatory Filings” fallback (RNS).
2026-05-11 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in authorized and issued shares, public float sufficiency confirmation, and other share capital related information. It is a regulatory compliance report related to share capital and public float status, not a financial report, earnings release, or management discussion. The document is structured as a regulatory submission to the exchange, with no financial statements or management commentary. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and compliance document that does not fit into more specific categories like share issue announcements or director dealings. The document length and content confirm it is not a brief announcement but a detailed regulatory return.
2026-05-06 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' and contains detailed sections typical of a full annual report, including Corporate Information, Financial Summary, Chairman's Statement, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Environmental, Social and Governance Report, Report of Directors, Report of Supervisors, Independent Auditor's Report, and full financial statements with notes. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content covers comprehensive financial performance, business review, product pipeline, and governance information for the fiscal year ended December 31, 2025. This matches the definition of an Annual Report (10-K). FY 2025
2026-04-29 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2026
Regulatory Filings Classification · 92% confidence The document is a standard monthly return (Form FF301) filed by an HKEX‐listed issuer summarizing movements in share capital, issued shares, and public float for the month. It is neither an earnings report, capital issuance announcement, nor AGM material but rather a routine regulatory filing under Hong Kong Listing Rules. It does not present new financial results or management commentary, nor is it a notice that another report has been published. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-04-08 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025
Annual Report Classification · 95% confidence The document is an 'Announcement of Annual Results' for the year ended December 31, 2025, for Shanghai Bio-heart Biological Technology Co., Ltd. It contains comprehensive audited consolidated financial statements, including the statement of profit or loss, statement of financial position, and detailed notes to the financial statements. While it is titled as an 'announcement', it provides the full substantive financial data and analysis for the fiscal year, which aligns with the definition of an Annual Report (10-K) or a comprehensive financial report. Given the detailed financial tables and notes provided, it functions as the primary annual financial disclosure. FY 2025
2026-03-26 English
VOLUNTARY ANNOUNCEMENT REGISTRATION OF IBERIS RDN SYSTEM IN THAILAND
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement regarding the registration of a medical product (Iberis RDN system) in Thailand. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding business operations and product development, it falls under the RNS (Regulatory Filings) category.
2026-03-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.